ANCA-associated Vasculitis: Causes & Treatment
ANCA-associated vasculitis is a rare autoimmune disease in which blood vessels become inflamed. Early diagnosis and treatment are essential to prevent serious organ damage.
Things worth knowing about "ANCA-associated vasculitis"
ANCA-associated vasculitis is a rare autoimmune disease in which blood vessels become inflamed. Early diagnosis and treatment are essential to prevent serious organ damage.
What is ANCA-associated vasculitis?
ANCA-associated vasculitis (AAV) is a group of rare autoimmune diseases in which the immune system mistakenly attacks and inflames the walls of small to medium-sized blood vessels. The acronym ANCA stands for anti-neutrophil cytoplasmic antibodies – specific antibodies found in the blood that serve as a hallmark diagnostic feature of this disease group. The inflammation can affect virtually any organ, but the kidneys, lungs, and upper respiratory tract are most commonly involved.
Subtypes of ANCA-associated vasculitis
AAV encompasses three main subtypes:
- Granulomatosis with polyangiitis (GPA), formerly known as Wegener granulomatosis: primarily affects the airways and kidneys.
- Microscopic polyangiitis (MPA): predominantly involves small blood vessels, frequently in the kidneys and lungs.
- Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss syndrome: often associated with asthma and elevated eosinophil counts.
Causes
The exact cause of AAV is not yet fully understood. It is believed that a combination of genetic predisposition and environmental factors – such as infections or exposure to certain chemicals – triggers the disease. ANCA antibodies activate neutrophils (immune cells), which then attack blood vessel walls, causing inflammation and tissue damage.
Symptoms
The symptoms of AAV vary widely depending on which organs are affected. Common symptoms include:
- General symptoms: fatigue, fever, weight loss, night sweats
- Kidneys: blood in the urine (haematuria), impaired kidney function, potentially leading to kidney failure
- Lungs: cough, shortness of breath, coughing up blood (haemoptysis)
- Upper respiratory tract: chronic sinusitis, nosebleeds, saddle nose deformity (in GPA)
- Skin: purpura (small bleeds beneath the skin surface), ulcers
- Nervous system: numbness, tingling, or weakness (mononeuritis multiplex)
- Eyes: inflammation, visual disturbances
Diagnosis
The diagnosis of AAV is based on several investigations:
- Blood tests: detection of ANCA antibodies (c-ANCA/PR3-ANCA in GPA; p-ANCA/MPO-ANCA in MPA and EGPA), inflammatory markers (CRP, ESR), kidney function tests
- Urinalysis: detection of blood or protein in the urine as a sign of kidney involvement
- Imaging: chest X-ray or CT scan of the lungs and sinuses
- Biopsy: tissue sampling from affected organs (e.g., kidney or lung) for histological confirmation of vasculitis
Treatment
Treatment of AAV follows two main phases:
Remission induction
The goal of this phase is to rapidly suppress active inflammation. Medications used include:
- Corticosteroids (e.g., prednisolone) at high doses to quickly reduce inflammation
- Cyclophosphamide or rituximab as immunosuppressive agents to dampen the overactive immune response
- In life-threatening cases, plasmapheresis (a blood purification procedure) may be added
Remission maintenance
After successful remission induction, treatment continues to prevent relapse:
- Azathioprine, methotrexate, or rituximab at lower doses
- Gradual tapering of corticosteroids
- Regular medical check-ups and laboratory tests to monitor disease activity and medication tolerance
Prognosis and disease course
Thanks to modern therapies, the prognosis of AAV has improved considerably. Many patients achieve stable remission. However, the disease is prone to relapse, making long-term medical follow-up essential. Severe organ damage, particularly to the kidneys, may persist permanently despite treatment.
References
- Jennette JC et al. - 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis & Rheumatism, 2013.
- Hellmich B et al. - EULAR recommendations for the management of ANCA-associated vasculitis. Annals of the Rheumatic Diseases, 2024.
- Falk RJ, Gross WL - Anti-neutrophil cytoplasmic autoantibody-associated disease: where do we go from here? Kidney International, 2011.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: ANCA-associated vasculitis